IOBT: רווח נקי למניה (EPS TTM) IO Biotech Corp

IO Biotech, Inc. (IOBT) develops innovative vaccines against melanoma and solid tumors, mitigating risks through partnerships with pharmaceutical behemoths. The current rolling annual EPS value on this GURU.Markets platform chart has reached -0.23. Drug delivery is ensured via strict temperature control through air carriers. However, the absence of commercial products leaves the company dependent on external financing and the results of clinical trials.

To objectively assess the operational efficiency of IO Biotech, Inc. (IOBT), investors must analyze real returns adjusted for the impact of share issuances. This rolling annual earnings per share snapshot reflects net profit over 12 months, allowing for a correlation between anti-tumor vaccine development costs and the company's capitalization to determine the long-term investment attractiveness of its innovative approach.